

2012

Insulin Resistance, Ceramide Accumulation, and Endoplasmic Reticulum Stress in Human Chronic Alcohol-Related Liver Disease

Lisa Longato

Kelsey Ripp

Mashiko Setshedi

Miroslav Dostalek

University of Rhode Island

Fatemeh Akhlaghi

University of Rhode Island, fakhlaghi@uri.edu

See next page for additional authors

Follow this and additional works at: https://digitalcommons.uri.edu/bps_facpubs

Citation/Publisher Attribution

Lisa Longato, Kelsey Ripp, Mashiko Setshedi, et al., "Insulin Resistance, Ceramide Accumulation, and Endoplasmic Reticulum Stress in Human Chronic Alcohol-Related Liver Disease," *Oxidative Medicine and Cellular Longevity*, vol. 2012, Article ID 479348, 17 pages, 2012. <https://doi.org/10.1155/2012/479348>
Available at: <https://doi.org/10.1155/2012/479348>

This Article is brought to you by the University of Rhode Island. It has been accepted for inclusion in Biomedical and Pharmaceutical Sciences Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons-group@uri.edu. For permission to reuse copyrighted content, contact the author directly.

Insulin Resistance, Ceramide Accumulation, and Endoplasmic Reticulum Stress in Human Chronic Alcohol-Related Liver Disease

Creative Commons License



This work is licensed under a [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/).

Authors

Lisa Longato, Kelsey Ripp, Mashiko Setshedi, Miroslav Dostalek, Fatemeh Akhlaghi, Mark Branda, Jack R. Wands, and Suzanne M. de la Monte

Research Article

Insulin Resistance, Ceramide Accumulation, and Endoplasmic Reticulum Stress in Human Chronic Alcohol-Related Liver Disease

Lisa Longato,¹ Kelsey Ripp,¹ Mashiko Setshedi,¹ Miroslav Dostalek,² Fatemeh Akhlaghi,² Mark Branda,¹ Jack R. Wands,¹ and Suzanne M. de la Monte^{1,3}

¹ Divisions of Gastroenterology and Neuropathology, Departments of Medicine, Pathology, Neurology, and Neurosurgery, The Liver Research Center, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI 02903, USA

² Clinical Pharmacokinetics Research Laboratory, University of Rhode Island, Kingston, RI 02881, USA

³ Pierre Galletti Research Building, Rhode Island Hospital, 55 Claverick Street, Room 419, Providence, RI 02903, USA

Correspondence should be addressed to Suzanne M. de la Monte, suzanne.delamonte_md@brown.edu

Received 15 October 2011; Revised 28 December 2011; Accepted 10 January 2012

Academic Editor: Florian Lang

Copyright © 2012 Lisa Longato et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Chronic alcohol-related liver disease (ALD) is mediated by insulin resistance, mitochondrial dysfunction, inflammation, oxidative stress, and DNA damage. Recent studies suggest that dysregulated lipid metabolism with accumulation of ceramides, together with ER stress potentiate hepatic insulin resistance and may cause steatohepatitis to progress. **Objective.** We examined the degree to which hepatic insulin resistance in advanced human ALD is correlated with ER stress, dysregulated lipid metabolism, and ceramide accumulation. **Methods.** We assessed the integrity of insulin signaling through the Akt pathway and measured proceramide and ER stress gene expression, ER stress signaling proteins, and ceramide profiles in liver tissue. **Results.** Chronic ALD was associated with increased expression of insulin, IGF-1, and IGF-2 receptors, impaired signaling through IGF-1R and IRS1, increased expression of multiple proceramide and ER stress genes and proteins, and higher levels of the C14, C16, C18, and C20 ceramide species relative to control. **Conclusions.** In human chronic ALD, persistent hepatic insulin resistance is associated with dysregulated lipid metabolism, ceramide accumulation, and striking upregulation of multiple ER stress signaling molecules. Given the role of ceramides as mediators of ER stress and insulin resistance, treatment with ceramide enzyme inhibitors may help reverse or halt progression of chronic ALD.

1. Introduction

Worldwide, alcohol abuse is one of the leading causes of morbidity and mortality from chronic liver disease [1, 2]. In its initial stages, alcohol-related liver disease (ALD) is characterized by hepatic steatosis, which is largely reversible. However, with continued chronic alcohol abuse, liver disease can progress through stages of steatohepatitis, followed by fibrosis, and then cirrhosis, and in the late stages, it may culminate in liver failure or hepatocellular carcinoma [3]. Previous studies linked chronic ALD to the combined effects of hepatic insulin resistance and toxicity mediated by inflammation, oxidative stress, mitochondrial

dysfunction, or acetaldehyde-induced adduct formation [4–7]. The consequences include impairments in hepatocellular survival, energy metabolism, and capacity to regenerate and remodel after injury. Together, these responses serve as potent stimuli for stellate cell activation and attendant fibrogenesis [8].

Recent studies have linked insulin resistance with inflammation and oxidative stress to dysregulated lipid metabolism and increased ceramide generation [9–11]. However, ceramides can further impair insulin signaling, mitochondrial function, and cell viability [12, 13]. Ceramides comprise a family of simple sphingolipids generated from fatty acid and sphingosine [13–15]. Although ceramides

are present at low levels within biological membranes, they make important contributions to cell membrane structure by participating in lipid raft formation. In addition, ceramides exert diverse regulatory effects on cell signaling pathways that mediate growth, proliferation, motility, adhesion, differentiation, senescence, and apoptosis [12, 13, 16–18].

Ceramides are generated via 3 main pathways: (1) *de novo* synthesis by coupling sphinganine to a long-chain fatty acid, yielding dihydroceramide; (2) hydrolysis of complex sphingolipids such as sphingomyelin or glycosphingolipids; (3) recycling after acylation of sphingosine, utilizing the “salvage pathway” [16, 17]. Ceramides cause insulin resistance by activating proinflammatory cytokines, inhibiting transmission of signals through phosphatidylinositol-3 kinase (PI3K) and Akt [19–22], and activating protein phosphatase 2A (PP2A) [23, 24]. Furthermore, ceramides can promote apoptosis by activating protein kinase C, PP1, caspases, and cathepsin D [16, 18]. Therefore, dysregulated lipid metabolism promoted by insulin resistance leads to increased generation of ceramides that exacerbate insulin resistance, inflammation, tissue injury, and cell death.

Emerging evidence suggests that ceramide production can be modulated by ethanol exposure, and that some of the hepatotoxic and degenerative effects of ethanol may be mediated by ceramide accumulation in liver. For example, ethanol increases ceramide levels by activating acidic sphingomyelinase [25], and ethanol-exposed hepatocyte cultures exhibit reduced levels of sphingomyelin and sphingosine, and increased levels of ceramide [26]. The findings that (1) mice deficient in acidic sphingomyelinase are resistant to ethanol-induced hepatic steatosis [27], and (2) ceramides contribute to the inhibitory effects of ethanol on AMPK phosphorylation [28] suggest that ceramides generated in ethanol exposed livers may cause liver injury.

Increased ceramide production can lead to endoplasmic reticulum (ER) stress and thereby contribute to the progression of ALD. ER stress can potentiate insulin resistance and lipolysis leading to increased ceramide production [29–32] and worsening of inflammation and insulin resistance. ER stress is caused by disruption of homeostatic mechanisms, causing unfolded proteins to accumulate, and reactive oxygen species (ROS) to form [33]. Normally, the ER adapts to stress by activating the unfolded protein response (UPR) [34, 35], which quickly increases the levels of ER stress sensor proteins including inositol-requiring enzyme 1 (IRE1), PKR-like ER-localized eIF2 α kinase (PERK), and the activating transcription factor 6 α (ATF-6 α ; ER membrane-anchored transcription factor). PERK and IRE1 activate ER stress networks by transmitting signals in response to protein misfolding or unfolding. PERK promotes a global arrest of protein synthesis by stimulating phosphorylation of eukaryotic translation initiation factor 2 α (eIF2 α), selective translation of ATF4, and upregulation of the transcription factor C/EBP homologous protein CHOP. IRE1 α promotes alternative splicing of XBP1, leading to increased transcription of chaperones and ER-associated protein degradation (ERAD) machinery. Activated ATF-6 promotes increased synthesis of chaperones and other components of the folding and ERAD machinery. Prolonged activation of the UPR

induces a pathological response leading to inflammation, injury, steatosis, and apoptosis [34, 36].

The above discussion highlights the importance of insulin resistance in ALD, and the probable interrelationship among insulin resistance, increased ceramide generation, and ER stress. We hypothesize that progressive ALD is mediated by the establishment of a harmful positive feedback loop whereby insulin resistance leads to lipolysis and toxic ceramide generation, which promotes ER stress, and both toxic ceramides and ER stress worsen insulin resistance. The present work examines the potential contributions of sustained insulin resistance, ER stress, and dysregulated lipid metabolism with increased activation of proceramide mechanisms and ceramide accumulation in human livers with chronic ALD.

2. Materials and Methods

2.1. Materials. Antibodies to ER stress markers were purchased from Cell Signaling (Danvers, MA). The Akt Total and Phospho 7-Plex Panels, Taqman Gene expression master mix, and Amplex Red Sphingomyelinase assay kit were purchased from Invitrogen (Carlsbad, CA). Bead-based magnetic immunoassays for cytokines quantification were from Biorad (Hercules, CA). MaxiSorp 96-well plates used for ELISAs were from Nunc (Thermo Fisher Scientific; Rochester, NY). Superblock-TBS, horseradish peroxidase-conjugated antibodies, and SuperSignal Enhanced Chemiluminescence Reagents were from Pierce Chemical Co (Rockford, IL). QIAzol Lysis Reagent for RNA extraction was obtained from Qiagen, Inc (Valencia, CA). The AMV 1st Strand cDNA Synthesis kit, the Universal Probe Library probes, and Reference gene assays were purchased from Roche Applied Science (Indianapolis, IN). The Serum Triglyceride Determination kit, monoclonal anti-ceramide, and synthetic oligodeoxynucleotides were purchased from Sigma-Aldrich Co (St. Louis, MO). All other monoclonal antibodies and immunodetection reagents were purchased from Abcam (Cambridge, MA), Upstate (Billerica, MA), Vector Laboratories (Burlingame, CA), Invitrogen (Carlsbad, CA), or Chemicon (Temecula, CA). Fine chemicals were purchased from CalBiochem (Carlsbad, CA) or Sigma-Aldrich (St. Louis, MO).

2.2. Source of Human Liver Tissue. Liver tissue biopsies from patients with chronic ALD and cirrhosis were obtained from the Liver Tissue Procurement Distribution System (NIH Contract no. N01-DK-9-2310). Normal human control liver biopsy tissue samples were obtained from the Lifespan-Rhode Island Hospital Tumor Bank (Providence, RI). Control liver samples represented remnant tissue from surgical biopsies performed for diagnosis. 10 samples were analyzed in each group. All specimens were deidentified and their use in this study was approved by the Lifespan Human Studies Committee and Investigational Review Board. Snap-frozen fresh tissues stored at -80°C were used for RNA, protein, and lipid studies. Formalin-fixed paraffin-embedded tissue sections were stained with hematoxylin and eosin (H&E) and with Masson's trichrome for histological assessment.

2.3. Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR) Assays. RNA extracted from fresh frozen liver using the RNeasy Mini Kit was reverse-transcribed using random oligonucleotide primers and the AMV 1st Strand cDNA Synthesis Kit. Gene expression was measured in duplicate reactions with a hydrolysis probe-based duplex qRT-PCR assay in which hypoxanthine-guanine phosphoribosyltransferase (HPRT) was included as a reference gene. Reactions (20 μ L) contained Taqman Gene expression master mix, 400 nM of gene-specific and HPRT primers, and 200 nM of HPRT (Y555 labeled) and gene of interest (FAM labeled) probes. Gene-specific primer sequences and matched probes were determined with the ProbeFinder Software (Roche, Indianapolis, IN) (Table 1). PCR amplifications were initiated by a 10-minute, 95°C denaturation step and followed by 45–50 2-step cycles of denaturation (15-seconds at 95°C) and annealing/extension (1-minute at 60°C). The amplifications were performed in a LightCycler 480 PCR machine (Roche, Indianapolis, IN). Fluorescence signals corresponding to the genes of interest were acquired in the FAM Channel (Em: 520–530 nm), and the HPRT signal was acquired in the Y555/HEX channel (Em: 550–568 nm). Results were analyzed using LightCycler Software 4.0. Alternatively, gene expression was measured in triplicate by qRT-PCR analysis using QuantiTect SYBR Green PCR Mix and gene-specific primer pairs [37], with results normalized to 18S rRNA as described [10].

2.4. Enzyme-Linked Immunosorbent Assay (ELISA). Liver homogenates were prepared in lysis buffer containing 50 mM Tris (pH 7.5), 150 mM NaCl, 5 mM EDTA (pH 8.0), 50 mM NaF, 0.1% Triton X-100, and protease and phosphatase inhibitors [38]. Direct binding ELISAs were performed in 96-well MaxiSorp plates. Protein homogenates (100 ng/50 μ L) were adsorbed to the well bottoms by overnight incubation at 4°C, and then blocked for 3 hours with 1% bovine serum albumin (BSA) in TRIS buffered saline (TBS). After washing, the samples were incubated with primary antibody (0.1–0.4 μ g/mL) for 1 hour at 37°C. Immunoreactivity was detected with horseradish-peroxidase-(HRP-) conjugated secondary antibody and Amplex UltraRed soluble fluorophore. Fluorescence intensity was measured (Ex 565 nm/Em 595 nm) in a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA). Ceramide immunoreactivity was quantified by ELISA as previously described [39].

2.5. Bead-Based Multiplex ELISA. We used bead-based multiplex ELISAs to assess the integrity of signaling through the insulin and IGF-1 receptors, insulin receptor substrate, type 1 (IRS-1), and downstream through Akt-related pathways using Akt Total and Phospho 7-Plex Panels. The Akt Total 7-Plex panel measured immunoreactivity to insulin receptor (IR), IGF-1 receptor (IGF-1R), IRS-1, Akt, proline-rich Akt substrate of 40 kDa (PRAS40), ribosomal protein S6 kinase (p70S6K), and glycogen synthase kinase 3 β (GSK-3 β). The Akt Phospho 7-Plex panel measured immunoreactivity to pYpY1162/1163-IR, pYpY1135/1136-IGF-1R, pS312-IRS-1, pS473-Akt,

pT246-PRAS40, pTpS421/424-p70S6K, and pS9-GSK3 β . Samples containing 100 μ g protein were incubated with the beads according to the manufacturer's protocol. Captured antigens were detected with secondary antibodies and phycoerythrin-conjugated anti-rabbit IgG. Proinflammatory cytokine levels in liver were measured with a 21-plex bead-based immunoassay (200 μ g protein/well). Plates were read in a Bio-Plex 200 system (Bio-Rad, Hercules, CA).

2.6. Liquid Chromatography, Tandem Mass Spectrometry (LC-MS-MS) for Quantification of Ceramides in Liver Tissue. Lipids were extracted for ceramide profiling as described [40, 41]. In brief, 60–70 mg of fresh frozen tissue were homogenized in 10 volumes of ice cold phosphate-buffered saline (PBS). 200 μ L of homogenate were extracted with isopropanol:water:ethyl acetate (30:10:60 by volume). The combined extracts were transferred to clean glass centrifuge tubes and evaporated at room temperature in a SpeedVac evaporator (Model SPD1010 Speed Vac System, Thermosavant, Holbrook, NY). The residues were redissolved in 100 μ L of methanol, vortex-mixed and then centrifuged; 5 μ L were injected in the analytical column. The system comprised a binary pump and autosampler (Shimadzu, Kyoto, Japan) coupled to an API 3200 triple quadrupole mass spectrometric detector (AB Sciex, Toronto, Ontario, Canada), equipped with a Turbo V source electrospray ionization (ESI) probe. The chromatographic data were collected and analyzed using the Analyst package (version 1.4.1., AB Sciex). Multiple reaction monitoring (MRM) scanning was used for mass spectral detection and quantification of C14-Ceramide (N-myristoyl-D-erythro-sphingosine), C16-Ceramide (N-palmitoyl-D-erythro-sphingosine), C18-Ceramide (N-stearoyl-D-erythro-sphingosine), C20-Ceramide (N-arachidonyl-D-erythro-sphingosine) and C24-Ceramide (N-lignoceroyl-D-erythro-sphingosine). C17-Ceramide (Heptadecanoyl-D-erythro-sphingosine) was used as an internal standard.

Thermo-Hypersil GOLD PFP (50 \times 2.1 mm, 3.0 μ m) analytical columns were used for chromatographic separation of the lipids using Buffer A (1.0 mmol/L ammonium acetate, 0.5% formic acid, v/v/v) and Buffer B (1.0 mmol/L ammonium acetate, 0.5% formic acid, HPLC-grade methanol, v/v/v). The mobile phase was comprised of solvent mixtures: A:B 50:50 (v/v) at 0.0 min; A:B 20:80 (v/v) for 0.01–8.0 min; A:B 5:95 (v/v) for 8.1–15.0 min; A:B 5:95 (v/v) for 15.1–20.0 min; A:B 5:95 (v/v) for 20.1–20.2 min; followed by column equilibration at A:B 50:50 (v/v) for five minutes, giving an injection cycle of 25 minutes. The flow rate was 250 μ L/min. Specific pairs of precursor/product ions were as follows: the ion transitions were C14-Ceramide (510.5 \rightarrow 492.4), C16-Ceramide (538.8 \rightarrow 520.5), C17-Ceramide (552.6 \rightarrow 534.4), C18-Ceramide (566.4 \rightarrow 548.4), C20-Ceramide (594.7 \rightarrow 576.2), and C24-Ceramide (650.6 \rightarrow 632.5). The retention times for C14-Ceramide, C16-Ceramide, C17-Ceramide, C18-Ceramide, C-20-Ceramide, and C24-Ceramide were 9.4, 10.0, 10.4, 10.7, 11.1, and 12.1 minutes, respectively. The ionization was set at electrospray positive ion mode

TABLE 1: List of primers used for qRT-PCR analysis of gene expression.

Primer		Sequence (5' → 3')	Position (mRNA)	Amplicon size (bp)	UPL probe no.
HERP	FOR	ACTGTCGTTGCAGAGATTGC	322	107	70
HERP	REV	GTTCCGGTCTCGGACTCCAT	410		
GRP-78/Bip	FOR	TGAAGGTGAAAAGACCCTGA	1654	107	15
GRP-78/Bip	REV	CAAAGGTGACTTCAATCTGTGG	1739		
EDEM-1	FOR	GCTGAGTGATTACCTTAGCCACA	5504	72	15
EDEM-1	REV	TGGACAGGAAAGCTCAGGAT	5556		
WARS	FOR	CTGGACGGGTGGACTTAGC	2667	77	74
WARS	REV	GAGGCCTGCCTAGACATCTG	2724		
PDI	FOR	TGAGGTCTGCGGAAAGTC	2226	95	16
PDI	REV	TCCGAGATACTGTCGTTTGTG	2299		
P58IPK	FOR	CTGAAGGAGCAAGAGACCATC	2182	76	87
P58IPK	REV	TTAATCCAAAGTCTAAGCCTGGATA	2233		
BAX	FOR	TGACCCCTGACCTCACTGT	763	82	29
BAX	REV	TGAGCAATTCCAGAGGCAGT	825		
CHOP	FOR	GTCATTGCCTTTCTCCTTCG	192	61	33
CHOP	REV	GTCCTCATACCAGGCTTCCA	233		
ATF-4	FOR	AAGGAGTTCGACTTGGATGC	1156	78	85
ATF-4	REV	ATCCAACGTGGTCAGAAGGT	1214		
CERS1	FOR	CAATGTGGGCATCCTTGTG	669	61	4
CERS1	REV	GGTGAACCTCAAGCTGCACG	711		
CERS2	FOR	ACTTCTGGTGGGAAACGTCTG	370	73	27
CERS2	REV	ACACGTCCATCTCGGTCTTC	423		
CERS4	FOR	GCAGGTGATACCACTTCG	944	91	62
CERS4	REV	TAACAGCAGACCAGAGAGC	1015		
CERS5	FOR	CATATGCGTGAGTTTCATTGC	1440	95	57
CERS5	REV	GTGGAACCTAAGGTGGGTTTCAGT	1513		
CERS6	FOR	GCTGGTTTCGACAAAGACG	468	60	2
CERS6	REV	TCTCACAGAACCTCGTCAGC	508		
UGCG	FOR	GATCAGGTGGACCAAACACTACG	1109	71	4
UGCG	REV	AGCATTCTGAAATGGCTCAC	1159		
GM3 Syn	FOR	TGCTGCTGATACTGGGTCTG	1710	77	26
GM3 Syn	REV	CAACAGAGAAGGGTTGTGACC	1766		
SMPD-1	FOR	GCACACCTGTCAATAGCTTCC	1142	78	52
SMPD-1	REV	TGGCCATCGCTTCATAGAG	1201		
SMPD-3	FOR	AGGACCTGCTGTCTGCTGTC	3956	76	79
SMPD-3	REV	TTGCAGCTCAATGGGTGAC	4013		
SPTLC-1	FOR	CGCGCTACTTGGAGAAAGA	1324	77	52
SPTLC-1	REV	CTCTGTTTGTTCACCGTGA	1381		
SPTLC-2	FOR	ATCGGTGTCGTTGTGGTTG	1659	82	21
SPTLC-2	REV	TGGTATGAGCTGCTGACAGG	1721		
CERD2	FOR	GACCATGTCTGGACGAAGACTTC	1626	77	34
CERD2	REV	CAACAGTCATGTTCTGCATCCC	1681		
CERD3	FOR	GGCAGTGGCTATAGCATATGG	367	85	12
CERD3	REV	AGACCAGGCGGATGAACTG	433		

Abbreviations: CERS: ceramide synthase; SMPD: sphingomyelin phosphodiesterase; UGCG: UDP glucose ceramide glycosyltransferase; SPTLC: serine palmitoyl transferase; CERD: ceramidase; GM3Syn: GM3-synthase; EDEM: ER degradation-enhancing α -mannosidase-like protein; CHOP: C/EBP homologous protein; p58IPK: inhibitor of interferon-induced and double stranded RNA activated kinase; GRP78: glucose regulated protein 78; ATF: activating transcription factor-4; HERP: homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1; WARS: tryptophanyl-tRNA synthetase.

and at a temperature of 150°C utilizing nitrogen for the drying and collision gas (curtain gas, 10 psi; collision gas, 3 psi; ionspray voltage, 5500 V; ion source gas 1, 25 psi; ion source gas 2, 25 psi). Separate stock solutions of all compounds each containing 1.0 mM were prepared in methanol. Working standard solutions of combined analytes were prepared by serial dilution in methanol. Calibration standards were prepared in concentrations ranging from 0.5 μ M to 500 μ M (0.1 μ M, 0.5 μ M, 1 μ M, 5 μ M, 10 μ M, 50 μ M, 100 μ M, 500 μ M). The internal standard was used at a final concentration of 20 nM.

2.7. Statistical Analysis. Data depicted in box plots reflect group medians (horizontal bar), 95% confidence interval limits (upper and lower box limits), and range (whiskers). Tabulated data reflect means \pm SEMs for each group. Data were analyzed using GraphPad Prism 5 software (GraphPad Software, Inc., San Diego, CA), and intergroup comparisons were made using Student's *t*-tests. Computer software generated *P* values are shown over the graph panels or in the tables.

3. Results

3.1. ALD Features. The 10 control livers all exhibited the normal chord-like architecture and were free of inflammation, steatosis, fibrosis, and cholestasis. Livers from the 10 chronic alcoholics had micronodular cirrhosis with steatohepatitis, apoptotic bodies, disorganization of the normal chord architecture, bile duct proliferation, and cholestasis. None of the livers exhibited dysplasia or hepatocellular carcinoma. Corresponding with the hepatic steatosis, the livers with ALD had significantly increased levels of neutral lipids as demonstrated with the Nile Red assay (Control: 9.41 ± 1.23 (FLU/g), ethanol: 13.35 ± 1.45 (FLU/g), *P* = 0.03). In contrast, mean triglyceride content was similar in the ALD and control livers (Control: 24.89 ± 2.95 (μ g/mg), ethanol: 24.38 ± 3.21 (μ g/mg)).

3.2. Cytokine Activation in Chronic ALD (Table 2). We used a 21-plex bead-based assay to measure proinflammatory cytokine and chemokine levels in relation to chronic ALD. Contrary to what might have been expected, chronic ALD was not associated with significantly increased levels of cytokines or chemokines in liver. Instead, the mean levels of proinflammatory cytokines IL-10, SDF-1 α , MCP, IL-1 β , IL-6 and TRAIL, and pro-fibrogenic cytokines VEGF, PDGF, and β -FGF were significantly lower in the chronic ALD relative to control livers. In contrast, the mean level of HGF, which is progrowth and antifibrogenic was significantly elevated in chronic ALD relative to control livers. However, qRT-PCR analysis demonstrated higher levels of IL-1 β , IL-6, and TNF- α in the ethanol group, with significant intergroup differences obtained with respect to IL-6 (Table 2). A similar phenomenon was observed in experimental models of chronic ethanol feeding [11]. The discrepancies between mRNA and protein could be due to increased release of newly synthesized cytokines in the context of chronic ethanol exposure.

3.3. Chronic ALD Is Associated with Impaired Hepatic Insulin Signaling. The qRT-PCR analyses demonstrated significantly reduced levels of IGF-2 and IRS-4, and increased levels of insulin, IGF-1, and IGF-2 receptor mRNA transcripts in chronic ALD relative to control livers. In contrast, the mRNA levels of insulin and IGF-1 polypeptide genes were similar in the two groups (Figure 1). Multiplex ELISAs also demonstrated significantly higher levels of insulin and IGF-1 receptor expression, and significantly reduced levels of IRS-1 protein in the ALD group (Figure 2). Although tyrosine phosphorylated insulin receptor levels were also increased in the ALD group, the ratio of phosphorylated/total insulin receptor was similar to control. In contrast, relative phosphorylation of the IGF-1 receptor was significantly reduced in the ALD versus control livers. ALD was also associated with significantly increased levels of S312 phosphorylation of IRS-1. S312 phosphorylation of IRS-1 inhibits IRS-1 signaling [42].

Additional studies characterized the effects of chronic ALD on downstream signaling through Akt pathways. Chronic ALD was associated with significantly increased levels of total and phosphorylated AKT levels, but similar levels of phospho/total Akt relative to control. ALD was associated with significantly reduced levels of total GSK-3 β , but significantly increased Ser9 phospho/total GSK-3 β , reflecting reduced levels of GSK-3 β activity. Correspondingly, we detected no significant effects of chronic ALD on the total, phosphorylated or phospho/total levels of proline-rich Akt substrate 40 kDa (PRAS 40) or p70S6 kinase, which mediate mTOR signaling (Table 3).

3.4. Chronic ALD Is Associated with Increased Activation of Proceramide Mechanisms in Liver. Previous studies in experimental animal models demonstrated that steatohepatitis from various causes, including chronic ethanol exposure, is associated with increased proceramide gene expression and ceramide levels in liver [10, 11]. To determine if human chronic ALD exhibits the same abnormalities, we measured mRNA levels of proceramide genes corresponding to the de novo synthesis (Ceramide synthases 1, 2, 4, 5, 6, and the subunits 1 (regulatory) and 2 (catalytic) of serine palmitoyl transferase subunit (SPTLC1 and 2)), catabolic (sphingomyelin phosphodiesterases 1 and 3 (SMPD-1 and SMPD-3) and ceramidases (CERD)), and to biosynthesis of complex sphingolipids (ganglioside GM3 synthase and UDP-glucose ceramide glucosyltransferase (UGCG)) pathways by qRT-PCR analysis (Table 4). Chronic ALD was associated with significantly increased expression of CERS1, CERS5, CERS6, and SPTLC1, reflecting increased ceramide biosynthesis, increased mRNA levels of SMPD1 and SMPD3, corresponding to increased levels of sphingomyelin hydrolysis, and decreased expression of CERD2, an enzyme responsible for deacylation of ceramide to sphingosine and fatty acids. In addition, chronic ALD was associated with significantly increased levels of GM3 synthase and UGCG, which mediate formation of complex sphingolipids from ceramides. We also measured acidic, neutral, and alkaline sphingomyelinase activities using commercial assay reagents and found significantly higher levels of all three in ALD relative to control livers (Figure 3).

TABLE 2: Effects of chronic ethanol exposure on proinflammatory cytokine levels in liver tissue.

	Control	Ethanol	P value
Protein			
LIF	58.19 ± 3.02	51.27 ± 3.06	
IL-10	18.20 ± 1.19	13.95 ± 0.97	0.008
MCP-1 (CCL2)	1793.48 ± 559.87	1123.61 ± 496.75	0.001
HGF	1305.97 ± 299.12	3887.81 ± 691.31	0.0001
SCF	30.14 ± 3.14	28.14 ± 1.29	
SDF (CXCL12)	79.25 ± 11.76	29.75 ± 2.76	<0.0001
VEGF	195.74 ± 12.52	120.72 ± 9.74	0.0003
PDGF	111.52 ± 9.94	59.73 ± 4.69	0.0002
IL-16	2769.95 ± 244.39	3058.46 ± 219.60	
GM-CSF	39.05 ± 1.29	33.54 ± 2.83	
β -FGF	948.78 ± 81.77	546.07 ± 46.79	0.0005
IP-10	734.19 ± 479.61	398.13 ± 96.21	
MIP-1	2279.33 ± 791.99	1177.78 ± 142.71	
IL-18	365.60 ± 48.50	672.60 ± 218.45	
β -NGF	41.76 ± 4.26	48.60 ± 8.14	
IL-8	806.30 ± 321.41	929.34 ± 185.10	
IFN- γ	6.66 ± 0.37	6.93 ± 0.55	
IL-1 β	123.40 ± 44.97	34.23 ± 7.75	0.028
IL-6	316.64 ± 108.93	126.60 ± 91.79	0.009
TNF- α	12.95 ± 1.03	15.93 ± 2.72	
TRAIL	61.14 ± 13.65	25.67 ± 2.84	0.01
mRNA			
IL-1 β	0.0254 ± 0.0098	0.0341 ± 0.0112	ns
IL-6	0.0670 ± 0.027	0.2727 ± 0.1033	0.0376
TNF- α	0.0253 ± 0.005	0.04072 ± 0.010	ns

Liver protein homogenates were used to measure immunoreactivity of the indicated cytokines by multiplex ELISA. Immunoreactivity was normalized to protein concentration and data are expressed as mean \pm SEM of fluorescence light units (arbitrary). mRNA was used to measure gene expression of TNF- α , IL-1 β , and IL-6 via qRT-PCR. Results were normalized to ribosomal 18S levels measured in the same samples. Intergroup comparisons were made using *t*-test and significant *P* values are indicated in the right columns.

3.5. Chronic ALD Results in Increased Ceramide Levels and Altered Ceramide Profiles in Liver. We measured ceramide immunoreactivity in liver tissue homogenates by ELISA and quantified the levels of ceramides C14:0, C16:0, C18:0, C20:0, and C24:0 by LC-MS/MS (Figure 3). Livers from patients with chronic ALD were associated with significantly higher levels of ceramide immunoreactivity relative to controls. The LC-MS/MS studies demonstrated the most abundant ceramide species in control human livers were C18:0, followed by C16:0, and then C20:0 and the least abundant was C14:0. In the chronic ALD samples, the mean levels of C14:0, C16:0, C18:0, and C20:0 were significantly elevated relative to control, whereas the levels of C24:0 were similar for the two groups.

3.6. ER Stress in ALD. Steatohepatitis, ceramide accumulation, and insulin resistance can each contribute to the activation of ER stress pathways, and ER stress can promote oxidative injury and inflammation, which cause ALD to progress. To determine if chronic ALD in humans is associated with increased ER stress, we measured mRNA expression of

multiple genes that mediate ER stress at various levels within the cascade [43]. Chronic ALD was associated with significant upregulation of the chaperone Bip/GRP78, the transcription factor ATF-4, the homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 (HERP) and tryptophanyl-tRNA synthetase (WARS) (Figure 4). ER degradation-enhancing α -mannosidase-like 1 (EDEM) and protein kinase inhibitor p58 (P58IPK) mRNA transcripts were also elevated in the ALD group, but the intergroup differences failed to reach statistical significance due to the large within group variances. Finally, since sustained UPR activation drives pathological responses leading to apoptosis, we measured expression of BAX and the transcription factor CHOP, and both were found to be significantly elevated in chronic ALD.

ELISAs were used to measure immunoreactivity to Bip/GRP78, CHOP, IRE-1 α , calnexin, the oxidoreductase ERO1 α , protein disulphur isomerase (PDI), PERK, phospho (Thr980) PERK, eIF2 α , and phospho (Ser51) eIF2 α . Chronic ALD was associated with significantly increased levels of Bip/GRP78, CHOP, IRE-1 α , calnexin, ERO-1 α , and PDI




FIGURE 1: Effects of chronic ALD on hepatic expression of insulin/IGF ligands and receptors, and IRS genes. RNA extracted from livers of control and chronic ALD subjects ($N = 8/\text{group}$) was reverse transcribed, and the cDNAs were used to measure gene expression by qPCR analysis. Graphs depict relative mRNA levels for (a) insulin, (b) insulin-like growth factor (IGF-1), (c) IGF-2, (d) insulin receptor (R), (e) IGF-1 receptor (IGF-1R), (f) IGF-2R, (g) insulin receptor substrate-1 (IRS-1), (h) IRS-2, and (i) IRS-4. Intergroup comparisons were made using Student's t -tests. Significant P values are shown over the graphs.

relative to control livers. In addition, the chronic ALD livers had significantly higher levels of PERK, p(Thr980)-PERK, and eIF2 α relative control. In contrast, levels of phosphorylated eIF2 α (Ser51) were similar for the two groups, while the relative level of phospho/total eIF2 α was significantly reduced in the chronic ALD relative to control group (Figure 5). Further Western blot analyses confirmed that ER stress pathways through PERK, Bip/GRP78, and CHOP were upregulated in chronic alcoholic livers (see Supplementary Figure 1 in Supplementary Material available online at doi:10.1155/2012/479348).

4. Discussion

This study was designed to gain a better understanding of the molecular pathogenesis of chronic progressive ALD in humans by determining if the abnormalities detected were similar to those previously identified in experimental animal models. Therefore, we examined several interrelated aspects of liver injury including (1) histopathology; (2) integrity

of insulin/IGF signaling through upstream and Akt downstream pathways; (3) activation of proinflammatory mediators; (4) ceramide production, accumulation, and profiles; (5) ER stress activation. Together, these approaches enabled us to characterize the nature and extent of hepatocellular dysfunction in human chronic progressive ALD. Moreover, the findings suggest that multipronged therapeutic strategies are needed to prevent or reduce ALD progression.

4.1. ALD Features. The histopathological studies demonstrated that all cases of chronic ALD included in this study had severe steatohepatitis with cirrhosis. As the livers were obtained from patients scheduled for liver transplantation, their clinical disease status was regarded as advanced. The presence of active steatohepatitis with conspicuous foci of apoptosis and necrosis indicates that the disease process was still progressing at the time of tissue sampling, thereby enabling us to determine the molecular and pathophysiological processes contributing to the ongoing liver injury and degeneration. The finding of reduced levels of




FIGURE 2: Effects of chronic ALD on insulin signaling mechanisms. Protein homogenates of liver were used in bead-based multiplex ELISAs to measure immunoreactivity corresponding to (a) insulin receptor (InR), (b) IGF-1 receptor (IGF-1R), (c) IRS-1, (d) p^Yp^Y1162/1163 InR, (e) p^Yp^Y1135/1136 IGF-1R, and (f) p^S312-IRS-1. Calculated phospho/total ratios of (g) InR, (h) IGF-1R, and (i) IRS-1 reflect relative levels of phosphorylation. Intergroup comparisons were made using Student's *t*-tests and significant *P* values are shown over the graphs.

TABLE 3: Effects of chronic ALD on the integrity of the Akt signaling pathway.

	Control	Ethanol	<i>P</i> value
Protein (Total)			
AKT	18599.50 ± 744.87	22377.37 ± 478.47	0.0002
GSK3β	2295.38 ± 250.09	1604.090 ± 208.06	0.017
PRAS40	462.13 ± 31.84	438.298 ± 15.13	
P70S6K	1204.38 ± 130.96	1258.14 ± 170.01	
Protein (phospho)			
p ^S 473-Akt	273.47 ± 720.05	252.78 ± 33.53	
p ^S 9-GSK3β	612.40 ± 155.72	636.30 ± 46.82	
p ^T 246-PRAS40	65.65 ± 5.42	78.07 ± 7.37	
p ^T p ^S 421/424-p70S6K	184.44 ± 23.30	114.32 ± 19.48	
Protein (Phospho/Total) * 100			
p ^S 473-Akt/Akt	1.43 ± 0.32	1.12 ± 0.14	
p ^S 9-GSK3β/GSK3β	28.42 ± 5.12	44.02 ± 8.15	0.038
p ^T 246-PRAS40/PRAS40	14.29 ± 2.26	17.65 ± 1.46	
p ^T p ^S 421/424-p70S6K/p70S6K	13.91 ± 4.14	9.01 ± 0.97	

Liver homogenates were used to measure immunoreactivity by multiplex ELISA. Phospho/total signaling protein levels were calculated. Immunoreactivity was normalized to protein concentration and data are expressed as mean ± SEM of fluorescence light units (arbitrary). Intergroup comparisons were made using *t*-tests. Significant *P* values are indicated in the right column.

TABLE 4: Effects of chronic ethanol consumption on hepatic expression of proceramide genes-biosynthetic pathways.

Protein	Control	Ethanol	P value
CerS1	0.542 ± 0.162	1.145 ± 0.228	0.025
CerS2	3634 ± 509.2	3982 ± 450	
CerS4	160.2 ± 36.36	172.7 ± 22.86	
CerS5	1.62 ± 0.22	3.62 ± 0.27	<0.0001
CerS6	15.70 ± 3.59	33.52 ± 5.48	0.0071
SPTLC-1	121.4 ± 9.29	253.3 ± 26.26	0.0001
SPTLC-2	2615 ± 444.8	3187 ± 309.5	
SMPD-1	685.7 ± 133.9	1214 ± 244.8	0.036
SMPD-3	765.4 ± 140.5	1353 ± 216.6	0.019
CERD2	6.524 ± 2.439	1.887 ± 0.3439	0.04
CERD3	5.583 ± 1.458	6.896 ± 1.853	
UGCG	282.6 ± 68.27	609.9 ± 174.5	0.0006
GM3Syn	56.21 ± 7.80	72.32 ± 6.981	0.006

RNA extracted from normal or chronic alcoholic livers ($N = 8/\text{group}$) was reverse transcribed, and the cDNAs were used to measure gene expression by qPCR analysis with gene-specific primer pairs in a duplex qPCR reaction, in which the genes of interest were co-amplified with HPRT for normalization (see Section 2 and Table 1). Table represents relative levels of gene expression for Ceramide synthases (CERS), UDP glucose ceramide glycosyltransferase (UGCG), ceramidases (CERD), GM3-synthase, serine palmitoyl transferase subunits (SPTLC), sphingomyelinases (SMPD). Intergroup comparisons were made using Student's *t*-tests and significant *P* values are shown over the graphs.

proinflammatory cytokines/chemokines was unexpected vis-à-vis the histopathological features of chronic active ALD. However, these findings correspond with results in previous experimental models of chronic ethanol feeding [11, 44]. Similarly, given the extensive degree of fibrosis, the finding of reduced levels of pro-fibrogenic markers was not expected, but it may reflect a host compensatory effort to restore liver structure.

4.2. Role of Insulin Resistance/Impaired Insulin Signaling.

Previous *in vitro* and experimental animal model studies demonstrated that short-term ethanol exposure or chronic ethanol feeding impairs insulin and IGF-1 signaling by inhibiting tyrosine phosphorylation of the insulin and IGF-1 receptors, and IRS-1 [45–50]. Impaired signaling through insulin and IGF-1 receptors was shown to be associated with reduced ligand-receptor binding and compensatory upregulation of the receptors, both at mRNA and protein levels [46, 48]. These effects correlated with inhibition of downstream signaling through Ras/Raf/Erk MAPK [45, 47, 49, 50], reduced DNA synthesis, and impaired capacity for the liver to regenerate following partial hepatectomy [48, 51]. In addition, the associated reduced transmission of signals downstream through the PI3K-Akt pathway increased apoptosis, DNA damage, mitochondrial dysfunction, and oxidative stress [46, 48, 52, 53].

The significantly increased levels of the insulin, IGF-1 and IGF-2 receptor expression in human cases of chronic ALD reflect insulin/IGF resistance. Correspondingly, the ratio of phosphorylated/total IGF-1 receptor was significantly reduced, confirming that chronic ALD impairs signaling through hepatic IGF-1 receptors in humans. Moreover, the significantly reduced expression of IGF-2 polypeptide in chronic ALD indicates that IGF-2 signaling was also impaired, but due to the combined effects of trophic

factor deficiency and receptor resistance. The finding that IRS-1 and IRS-4 expressions were significantly reduced in chronic ALD indicates that insulin/IGF receptor signaling was further impaired by reduced capacity to transmit signals downstream through IRS docking proteins. An additional abnormality contributing to hepatic insulin/IGF resistance in human chronic ALD was the significantly increased levels of S312 phosphorylation of IRS-1; S312 phosphorylation inhibits IRS-1 signaling [42]. This is the first study to demonstrate impairments in insulin/IGF/IRS signaling in human chronic ALD. However, earlier studies in which mainly peripheral blood and leukocytes were available for study showed that patients with alcoholic cirrhosis had peripheral insulin resistance [54–59] with binding and postbinding defects in insulin target organ cells [54, 55, 59]. Moreover, analysis of brains from human alcoholics demonstrated chronic insulin resistance in structural targets of alcohol-induced neurodegeneration [37]. Therefore, these earlier studies provide evidence that ethanol-induced insulin resistance is a multisystem disease that is somehow linked to chronic progressive liver disease. The question is, “what is the mechanism?”

To examine the effects of impaired insulin/IGF/IRS signaling through the downstream Akt pathway, we used multiplex ELISAs to measure total and phosphorylated levels of Akt, GSK-3 β , PRAS40, and p70S6K. In contrast to the findings in experimental animals in which impairments in insulin/IGF/IRS signaling were associated with reduced AKT and increased GSK-3 β activation [48], human chronic ALD was not associated with significant impairments in signaling through survival or metabolic pathways. Instead, the findings of increased Akt and phospho-Akt, but similar phospho/total Akt relative control, and reduced total GSK-3 β , phospho-Ser9/GSK-3 β , and phospho-Ser9/total GSK-3 β indicate that Akt activation was preserved while GSK-3 β was relatively inhibited. Therefore, survival and metabolic




FIGURE 3: Effects of chronic ALD on proceramide pathway activation in liver. Using a fluorogenic assay, (a) neutral, (b) acid, and (c) alkaline sphingomyelinase activities were measured in homogenates of liver from control or chronic ALD subjects. Hepatic ceramide profiles were measured in lipid extracts by LC/MS/MS. (d) CerC14:0, (e) CerC16:0, (f) CerC18:0, (g) CerC20:0, and (h) CerC24:0 levels are expressed as pg/mg protein. (i) Total ceramide immunoreactivity was measured by direct-binding ELISA. Intergroup comparisons were made using Student's *t*-tests and significant *P* values are shown over the graphs.

signaling through the Akt pathway were found to be intact in human chronic ALD. Similarly, activation of the mTOR networks via p70S6k and PRAS40 was intact. The discrepancy between the impairments in upstream signaling through insulin/IGF/IRS and intact downstream signaling could be explained by the fact that other signaling mechanisms, including those mediated by hepatocyte growth factor or epidermal growth factor, can also activate Akt pathways independent of IRS-dependent networks [60, 61]. Future studies will characterize the mechanisms by which prosurvival and prometabolic signaling are maintained vis-à-vis chronic ALD-induced inhibition of insulin/IGF/IRS pathways.

4.3. Role of Ceramides in Chronic ALD. Although hepatic steatosis is generally regarded as benign and reversible, persistent injury and inflammation can cause steatohepatitis to become chronic and progressive. Two factors that probably contribute to ALD progression include (1) aberrant

shifts in membrane lipid composition leading to disrupted intracellular signaling [29, 62, 63]; (2) the accumulation of toxic lipids that mediate cellular pathology via increased oxidative stress, ROS generation, adduct formation, and ER stress. Growth in our understanding of how abnormal accumulation and composition of lipids contribute to chronic insulin resistance diseases has been furthered by modern lipidomic approaches. For example, besides the histopathological differences, nonalcoholic steatohepatitis (NASH) is distinguished from nonalcoholic fatty liver disease (NAFLD) based on the composition of lipids accumulated in hepatocytes [64].

Diacylglycerol (DAG), free fatty acids, free cholesterol, and ceramides can all have lipotoxic effects in hepatocytes [31, 65, 66]. However, we focused our studies on the potential contributions of ceramides in chronic ALD because (1) ceramides have demonstrated roles in the pathogenesis of steatohepatitis in experimental models of chronic ethanol or high-fat diet feeding [10, 11]; (2) ceramides can promote




FIGURE 4: Effects of chronic ALD on hepatic ER stress gene activation. RNA extracted from livers of control and chronic ALD subjects ($N = 8/\text{group}$) was reverse transcribed, and the cDNAs were used to measure gene expression by duplex qPCR assays in which the gene of interest was coamplified with hypoxanthine-guanine phosphoribosyltransferase (HPRT) as control (see Section 2 and Table 1). Graphs depict relative levels of gene expression for (a) BAX, (b) ER degradation-enhancing α -mannosidase-like protein (EDEM), (c) C/EBP homologous protein (CHOP), (d) inhibitor of interferon-induced and double stranded RNA activated kinase (p58IPK), (e) glucose regulated protein 78 (GRP78), (f) activating transcription factor-4 (ATF-4), (g) homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 (HERP), and (h) tryptophanyl-tRNA synthetase (WARS). Intergroup comparisons were made using Student's t -tests. Significant P values are shown over the graphs.




FIGURE 5: Chronic ALD results in increased hepatic ER stress. ER stress protein expression and phosphorylation were measured by ELISA using HRP-conjugated secondary antibody and Amplex UltraRed soluble fluorophore. Graphs depict immunoreactivity corresponding to (a) Bip/GRP78, (b) CHOP, (c) inositol requiring enzyme-1 (IRE-1), (d) calnexin, (e) endoplasmic oxidoreductin-1 (ERO-1), (f) protein disulphide isomerase (PDI), (g) PERK, (h) phospho PERK (Thr980), (i) eIF2- α , and (j) phospho eIF2- α (Ser51). Fluorescence was measured (Ex 530 nm/Em 590 nm) in a Spectramax M5 microplate reader (FLU = fluorescence light units). Intergroup comparisons were made by Student's *t*-test analysis. Significant *P* values are shown over the graphs.

insulin resistance, inflammation, and oxidative stress in various insulin resistance disease states [67–69], including Type 2 diabetes and obesity [70–72]; (3) ceramides impair Akt/PKB signaling through activation of protein phosphatase 2A (PP2A) which dephosphorylates Akt [18, 73] and inhibition of protein-kinase-C- ζ - (PKC- ζ -) dependent translocation of Akt to the plasma membrane, which is required for its function [22]. Although the Akt pathway was not inhibited in human chronic ALD, taken in the context of the impairments detected in experimental models, it is possible that the abnormality does occur in the earlier and less severe stages of ALD, but compensatory mechanisms restore these functions via activation of other signaling networks, for example, those driven by EGF or HGF. As demonstrated with the multiplex array analysis, HGF expression was strikingly increased in chronic ALD relative to control livers.

Corresponding with the findings in experimental models of alcohol- and high-fat-diet-induced steatohepatitis, human livers with severe chronic ALD had significantly increased expression of multiple proceramide genes as well as increased levels of ceramide immunoreactivity. The robustness and significance of this response are underscored by the constitutive upregulation of proceramide genes in the biosynthetic, catabolic, and salvage pathways, as well as increased activation of acidic and neutral sphingomyelinases. Mechanistically, insulin resistance promotes lipolysis, and increased lipolysis results in the breakdown (hydrolysis) of complex lipids, thereby promoting increased levels of ceramide. In addition, ceramides can be generated via the salvage pathway due to increased levels of precursor lipids. Conceivably, the pathogenic signaling that activates lipolysis vis-à-vis chronic steatohepatitis may also initiate proceramide cascades by increasing gene expression and enzymatic activity. The increased levels of ceramide synthase gene expression could be explained by increased fatty acid load that characteristically occurs with steatohepatitis, irrespective of etiology [10, 11, 74].

We extended our analyses by characterizing the ceramide profiles in liver tissue using LC-MS/MS. The rationale was that (1) ceramides associated with specific fatty acids can have diverse biological functions and can be generated in response to diverse stimuli [75, 76]; (2) intracellular partitioning of fatty acids and their metabolites plays a role in mediating insulin resistance and lipotoxicity [77]. Coupling liquid chromatography with tandem mass spectrometry enabled us to identify the different ceramide species in liver based on retention time and specific mass transition using synthetic reference standards [78].

The LC/MS/MS studies demonstrated that the ceramide profiles in chronic ALD differed significantly from those in control livers due to the relatively higher levels of C14:0, C16:0, C18:0, and C20:0. Previously it was shown that increased levels of C16:0, and also C24:0 ceramides could promote cell death [79, 80], while C18:0 ceramide inhibits cell growth [81]. Therefore, the ongoing cell death associated with chronic progressive ALD in humans could be mediated in part by increased levels of C16:0 ceramide. Mechanistically, CERS1 has a high specificity for C18:0-CoA generating C18:0-ceramide, and CERS2 and CERS4 mainly synthesize

C20:0-, C22:0-, C24:1-, C24:0-, C26:1-, and C26:0-ceramide. In contrast, shorter chain ceramides like C14:0, C16:0 are primarily generated by CerS5 and CerS6 [76]. The qRT-PCR analyses demonstrated significantly higher levels of CERS1, CERS5, and CERS6 in human chronic ALD, which could partly account for the associated shifts in hepatic ceramide profiles. As the field of lipidomics grows, our ability to interpret these types of results in relation to disease pathogenesis, including insulin resistance, lipotoxicity, and inflammation will improve. In addition, we may arrive at the point where targeting specific proceramide mediators can be used to therapeutically modulate ceramide membrane composition.

4.4. ER Stress in Progressive ALD. Insulin resistance, inflammation, and ceramide accumulation can promote ER stress, and ER stress exacerbates insulin resistance, inflammation, oxidative stress, and ceramide accumulation [35, 82–88]. Moreover, ethanol exposure in experimental animal models leads to increased activation of ER stress responses in liver [36, 89, 90]. The studies herein demonstrate that in human chronic progressive ALD, ER stress signaling is strikingly upregulated via multiple mechanisms including (1) Bip/GRP78, which is an important chaperone protein; (2) IRE-1 α , which activates JNK; (3) PERK, which promotes global arrest of protein synthesis, translation of ATF4, and upregulation of CHOP; (4) CHOP, which activates caspases and inhibits Bcl2 pro-survival function by activating BAX. The increased levels of ATF-4 in chronic ALD correspond with the significantly higher levels of chaperones and other components of the folding and ERAD machinery, that is, PDI and GRP78. In addition, chronic ALD was found to be associated with significantly increased expression of calnexin and ERO-1 α . Calnexin binds glycosylated proteins after they pass into the ER, while ERO1 and BAX are activated by CHOP. Therefore, consequences of constitutive activation of the UPR in chronic ALD progression include (1) increased apoptosis via CHOP [91]; (2) disruption of calcium and redox homeostasis [34]; (3) further dysregulation of lipid homeostasis [92] leading to enhanced production of cholesterol and triglycerides via activation of the transcription factor SREBP.

5. Summary and Conclusions

Human chronic progressive ALD is associated with impaired insulin and IGF signaling through insulin/IGF receptors, IRS-1, and IRS-4. However, downstream signaling through Akt pathways were found intact, probably due to compensatory adaptive responses such as signaling through other receptors such as EGF or HGF. In contrast to the histopathological findings, chronic ALD was not associated with increased activation of proinflammatory cytokines or chemokines or profibrogenic markers. The most striking abnormalities in human livers with advanced chronic ALD were prominent activation of proceramide mechanisms with ceramide accumulation and altered ceramide profiles, and increased activation of the UPR via several pathways and

at multiple levels of the network. The aberrant shifts in ceramide profiles could have contributed to the insulin resistance and continued activation of prodeath mechanisms. At the late stages of disease examined, it is not possible to designate any single mechanism as the cause of ALD progression. However, the findings in experimental animal models suggest that one of the earliest abnormalities in chronic steatohepatitis is insulin resistance. We hypothesize that once steatohepatitis becomes sufficiently severe and long-standing, hepatic insulin resistance mechanisms with activation of mal-signaling cascades become initiated whereby lipolysis leads to increased ceramide generation and accumulation in membranes including the ER and plasma membrane. Ceramide accumulation in the ER promotes ER stress, and ceramide incorporation into lipid rafts exacerbates insulin resistance, inflammation, oxidative stress, and proapoptosis signaling. Increased oxidative stress leads to ROS formation, lipid peroxidation, DNA damage, and cell death. Altogether, the findings herein suggest that therapeutic prevention or reduction of ALD progression requires multipronged strategies to reverse or stabilize the consequences of hepatic insulin resistance and dysregulated lipid metabolism.

Authors' Contribution

L. Longato, K. Ripp, and M. Setshedi contributed equally to this paper.

Acknowledgment

This work is supported by AA-11431, AA-12908, and AA-16126 from the National Institutes of Health.

References

- [1] A. M. Miller, N. Horiguchi, W.-I. Jeong, S. Radaeva, and B. Gao, "Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines," *Alcoholism*, vol. 35, no. 5, pp. 787–793, 2011.
- [2] R. S. O Shea, S. Dasarathy, and A. J. McCullough, "Alcoholic liver disease," *American Journal of Gastroenterology*, vol. 105, no. 1, pp. 14–32, 2010.
- [3] V. Purohit, B. Gao, and B. J. Song, "Molecular mechanisms of alcoholic fatty liver," *Alcoholism*, vol. 33, no. 2, pp. 191–205, 2009.
- [4] B. Gao, E. Seki, D. A. Brenner et al., "Innate immunity in alcoholic liver disease," *American Journal of Physiology*, vol. 300, no. 4, pp. G516–G525, 2011.
- [5] C. S. Lieber, "Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis," *Alcohol*, vol. 34, no. 1, pp. 9–19, 2004.
- [6] D. Seth, P. S. Haber, W.-K. Syn, A. M. Diehl, and C. P. Day, "Pathogenesis of alcohol-induced liver disease: classical concepts and recent advances," *Journal of Gastroenterology and Hepatology*, vol. 26, no. 7, pp. 1089–1105, 2011.
- [7] M. Setshedi, J. R. Wands, and S. M. De La Monte, "Acetaldehyde adducts in alcoholic liver disease," *Oxidative Medicine and Cellular Longevity*, vol. 3, no. 3, pp. 178–185, 2010.
- [8] S. L. Friedman, "Mechanisms of hepatic fibrogenesis," *Gastroenterology*, vol. 134, no. 6, pp. 1655–1669, 2008.
- [9] S. M. De La Monte, L. Longato, M. Tong, S. Denucci, and J. R. Wands, "The liver-brain axis of alcohol-mediated neurodegeneration: role of toxic lipids," *International Journal of Environmental Research and Public Health*, vol. 6, no. 7, pp. 2055–2075, 2009.
- [10] L. E. Lyn-Cook, M. Lawton, M. Tong et al., "Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis," *Journal of Alzheimer's Disease*, vol. 16, no. 4, pp. 715–729, 2009.
- [11] M. Setshedi, L. Longato, D. R. Petersen et al., "Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis," *Alcoholism*, vol. 35, no. 12, pp. 2139–2151, 2011.
- [12] W. L. Holland and S. A. Summers, "Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism," *Endocrine Reviews*, vol. 29, no. 4, pp. 381–402, 2008.
- [13] S. A. Summers, "Ceramides in insulin resistance and lipotoxicity," *Progress in Lipid Research*, vol. 45, no. 1, pp. 42–72, 2006.
- [14] B. Liu et al., "Sphingomyelinases in cell regulation," *Seminars in Cell & Developmental Biology*, vol. 8, pp. 311–322, 1997.
- [15] C. P. Reynolds, B. J. Maurer, and R. N. Kolesnick, "Ceramide synthesis and metabolism as a target for cancer therapy," *Cancer Letters*, vol. 206, no. 2, pp. 169–180, 2004.
- [16] L. A. Cowart, "Sphingolipids: players in the pathology of metabolic disease," *Trends in Endocrinology and Metabolism*, vol. 20, no. 1, pp. 34–42, 2009.
- [17] Y. A. Hannun and L. M. Obeid, "Principles of bioactive lipid signalling: lessons from sphingolipids," *Nature Reviews Molecular Cell Biology*, vol. 9, no. 2, pp. 139–150, 2008.
- [18] P. P. Ruvolo, "Intracellular signal transduction pathways activated by ceramide and its metabolites," *Pharmacological Research*, vol. 47, no. 5, pp. 383–392, 2003.
- [19] N. A. Bourbon, L. Sandrasegarane, and M. Kester, "Ceramide-induced inhibition of Akt is mediated through protein kinase C ζ . Implications for growth arrest," *Journal of Biological Chemistry*, vol. 277, no. 5, pp. 3286–3292, 2002.
- [20] E. Hajdуч, A. Balendran, I. H. Batty et al., "Ceramide impairs the insulin-dependent membrane recruitment of protein kinase B leading to a loss in downstream signalling in L6 skeletal muscle cells," *Diabetologia*, vol. 44, no. 2, pp. 173–183, 2001.
- [21] T. C. A. Nogueira, G. F. Anhê, C. R. O. Carvalho, R. Curi, S. Bordin, and A. R. Carpinelli, "Involvement of phosphatidylinositol-3 kinase/AKT/PKC ζ / λ pathway in the effect of palmitate on glucose-induced insulin secretion," *Pancreas*, vol. 37, no. 3, pp. 309–315, 2008.
- [22] D. J. Powell, E. Hajdуч, G. Kular, and H. S. Hundal, "Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKC ζ -dependent mechanism," *Molecular and Cellular Biology*, vol. 23, no. 21, pp. 7794–7808, 2003.
- [23] J. A. Chavez, T. A. Knotts, L. P. Wang et al., "A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids," *Journal of Biological Chemistry*, vol. 278, no. 12, pp. 10297–10303, 2003.
- [24] S. Stratford, K. L. Hoehn, F. Liu, and S. A. Summers, "Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B," *Journal of Biological Chemistry*, vol. 279, no. 35, pp. 36608–36615, 2004.
- [25] I. V. Deaciuc, M. Nikolova-Karakashian, F. Fortunato, E. Y. Lee, D. B. Hill, and C. J. McClain, "Apoptosis and dysregulated ceramide metabolism in a murine model of alcohol-enhanced

- lipopolysaccharide hepatotoxicity," *Alcoholism*, vol. 24, no. 10, pp. 1557–1565, 2000.
- [26] A. V. Viktorov and V. A. Yurkiv, "Effects of ethanol and lipopolysaccharide on the sphingomyelin cycle in rat hepatocytes," *Bulletin of Experimental Biology and Medicine*, vol. 146, no. 6, pp. 753–755, 2008.
- [27] C. García-Ruiz, A. Colell, M. Mari et al., "Defective TNF- α -mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice," *Journal of Clinical Investigation*, vol. 111, no. 2, pp. 197–208, 2003.
- [28] S. Liangpunsakul, M. S. Sozio, E. Shin et al., "Inhibitory effect of ethanol on AMPK phosphorylation is mediated in part through elevated ceramide levels," *American Journal of Physiology*, vol. 298, no. 6, pp. G1004–G1012, 2010.
- [29] N. Anderson and J. Borlak, "Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis," *Pharmacological Reviews*, vol. 60, no. 3, pp. 311–357, 2008.
- [30] N. Kaplowitz, A. T. Tin, M. Shinohara, and C. Ji, "Endoplasmic reticulum stress and liver injury," *Seminars in Liver Disease*, vol. 27, no. 4, pp. 367–377, 2007.
- [31] H. Malhi and G. J. Gores, "Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease," *Seminars in Liver Disease*, vol. 28, no. 4, pp. 360–369, 2008.
- [32] S. S. Rajan, V. Srinivasan, M. Balasubramanyam, and U. Tatu, "Endoplasmic reticulum (ER) stress & diabetes," *Indian Journal of Medical Research*, vol. 125, no. 3, pp. 411–424, 2007.
- [33] G. S. Hotamisligil, "Endoplasmic reticulum stress and the inflammatory basis of metabolic disease," *Cell*, vol. 140, no. 6, pp. 900–917, 2010.
- [34] H. Malhi and R. J. Kaufman, "Endoplasmic reticulum stress in liver disease," *Journal of Hepatology*, vol. 54, no. 4, pp. 795–809, 2011.
- [35] U. Özcan, Q. Cao, E. Yilmaz et al., "Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes," *Science*, vol. 306, no. 5695, pp. 457–461, 2004.
- [36] L. Dara et al., "The contribution of endoplasmic reticulum stress to liver diseases," *Hepatology*, vol. 53, pp. 1752–1763, 2011.
- [37] S. M. De La Monte, M. Tong, A. C. Cohen, D. Sheedy, C. Harper, and J. R. Wands, "Insulin and insulin-like growth factor resistance in alcoholic neurodegeneration," *Alcoholism*, vol. 32, no. 9, pp. 1630–1644, 2008.
- [38] N. Moroz, M. Tong, L. Longato, H. Xu, and S. M. De La Monte, "Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus," *Journal of Alzheimer's Disease*, vol. 15, no. 1, pp. 29–44, 2008.
- [39] S. M. De La Monte, M. Tong, V. Nguyen, M. Setshedi, L. Longato, and J. R. Wands, "Ceramide-mediated insulin resistance and impairment of cognitive-motor functions," *Journal of Alzheimer's Disease*, vol. 21, no. 3, pp. 967–984, 2010.
- [40] J. Bielawski, J. S. Pierce, J. Snider, B. Rembiesa, Z. M. Szulc, and A. Bielawska, "Comprehensive quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry," *Methods in Molecular Biology*, vol. 579, pp. 443–467, 2009.
- [41] J. Bielawski, Z. M. Szulc, Y. A. Hannun, and A. Bielawska, "Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry," *Methods*, vol. 39, no. 2, pp. 82–91, 2006.
- [42] V. Aguirre, E. D. Werner, J. Giraud, Y. H. Lee, S. E. Shoelson, and M. F. White, "Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action," *Journal of Biological Chemistry*, vol. 277, no. 2, pp. 1531–1537, 2002.
- [43] S. Gupta, A. Samali, U. Fitzgerald, and S. Deegan, "Methods for monitoring endoplasmic reticulum stress and the unfolded protein response," *International Journal of Cell Biology*, vol. 2010, Article ID 830307, 11 pages, 2010.
- [44] S. M. De La Monte, S. M. Denucci, M. Tong et al., "Rat strain differences in susceptibility to alcohol-induced chronic liver injury and hepatic insulin resistance," *Gastroenterology Research and Practice*, vol. 2010, Article ID 312790, 16 pages, 2010.
- [45] K. Banerjee, L. Mohr, J. R. Wands, and S. M. De La Monte, "Ethanol inhibition of insulin signaling in hepatocellular carcinoma cells," *Alcoholism*, vol. 22, no. 9, pp. 2093–2101, 1998.
- [46] S. M. De La Monte, J. E. Yeon, M. Tong et al., "Insulin resistance in experimental alcohol-induced liver disease," *Journal of Gastroenterology and Hepatology*, vol. 23, no. 8, pp. e477–e486, 2008.
- [47] L. Mohr, S. Tanaka, and J. R. Wands, "Ethanol inhibits hepatocyte proliferation in insulin receptor substrate 1 transgenic mice," *Gastroenterology*, vol. 115, no. 6, pp. 1558–1565, 1998.
- [48] M. Pang, S. M. de la Monte, L. Longato et al., "PPAR δ agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair," *Journal of Hepatology*, vol. 50, no. 6, pp. 1192–1201, 2009.
- [49] Y. Sasaki, N. Hayashi, T. Ito, H. Fusamoto, T. Kamada, and J. R. Wands, "Influence of ethanol on insulin receptor substrate-1-mediated signal transduction during rat liver regeneration," *Alcohol and Alcoholism*, vol. 29, no. 1, supplement, pp. 99–106, 1994.
- [50] Y. Sasaki and J. R. Wands, "Ethanol impairs insulin receptor substrate-1 mediated signal transduction during rat liver regeneration," *Biochemical and Biophysical Research Communications*, vol. 199, no. 1, pp. 403–409, 1994.
- [51] J. R. Wands, E. A. Carter, N. L. R. Bucher, and K. J. Isselbacher, "Inhibition of hepatic regeneration in rats by acute and chronic ethanol intoxication," *Gastroenterology*, vol. 77, no. 3, pp. 528–531, 1979.
- [52] M. J. J. Ronis, J. R. Wands, T. M. Badger, S. M. De La Monte, C. H. Lang, and J. Calissendorff, "Alcohol-induced disruption of endocrine signaling," *Alcoholism*, vol. 31, no. 8, pp. 1269–1285, 2007.
- [53] J. E. Yeon, S. Califano, J. Xu, J. R. Wands, and S. M. De La Monte, "Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver," *Hepatology*, vol. 38, no. 3, pp. 703–714, 2003.
- [54] A. T. Blei, D. C. Robbins, and E. Drobny, "Insulin resistance and insulin receptors in hepatic cirrhosis," *Gastroenterology*, vol. 83, no. 6, pp. 1191–1199, 1982.
- [55] J. Iversen, H. Vilstrup, and N. Tygstrup, "Kinetics of glucose metabolism in relation to insulin concentrations in patients with alcoholic cirrhosis and in healthy persons," *Gastroenterology*, vol. 87, no. 5, pp. 1138–1143, 1984.
- [56] Y. T. Kruszynska, P. D. Home, and N. McIntyre, "Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis," *Hepatology*, vol. 14, no. 1, pp. 103–111, 1991.
- [57] M. J. Muller, O. Willmann, A. Rieger et al., "Mechanism of insulin resistance associated with liver cirrhosis," *Gastroenterology*, vol. 102, no. 6, pp. 2033–2041, 1992.
- [58] E. A. Sotaniemi, K. Keinanen, and J. T. Lahtela, "Carbohydrate intolerance associated with reduced hepatic glucose phosphorylating and releasing enzyme activities and peripheral

- insulin resistance in alcoholics with liver cirrhosis," *Journal of Hepatology*, vol. 1, no. 3, pp. 277–290, 1985.
- [59] R. Taylor, R. J. Heine, and J. Collins, "Insulin action in cirrhosis," *Hepatology*, vol. 5, no. 1, pp. 64–71, 1985.
- [60] C. Ponzetto, A. Bardelli, Z. Zhen et al., "A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family," *Cell*, vol. 77, no. 2, pp. 261–271, 1994.
- [61] L. Trusolino, A. Bertotti, and P. M. Comoglio, "MET signalling: principles and functions in development, organ regeneration and cancer," *Nature Reviews Molecular Cell Biology*, vol. 11, no. 12, pp. 834–848, 2010.
- [62] E. Ikonen and S. Vainio, "Lipid microdomains and insulin resistance: is there a connection?" *Science's STKE*, vol. 2005, no. 268, p. pe3, 2005.
- [63] J. I. Inokuchi, "Membrane microdomains and insulin resistance," *FEBS Letters*, vol. 584, no. 9, pp. 1864–1871, 2010.
- [64] P. Puri, R. A. Baillie, M. M. Wiest et al., "A lipidomic analysis of nonalcoholic fatty liver disease," *Hepatology*, vol. 46, no. 4, pp. 1081–1090, 2007.
- [65] N. Alkhoury, L. J. Dixon, and A. E. Feldstein, "Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal," *Expert Review of Gastroenterology and Hepatology*, vol. 3, no. 4, pp. 445–451, 2009.
- [66] B. A. Neuschwander-Tetri, "Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites," *Hepatology*, vol. 52, no. 2, pp. 774–788, 2010.
- [67] W. L. Holland, J. T. Brozinick, L. P. Wang et al., "Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance," *Cell Metabolism*, vol. 5, no. 3, pp. 167–179, 2007.
- [68] J. Turinsky, D. M. O'Sullivan, and B. P. Bayly, "1,2-diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo," *Journal of Biological Chemistry*, vol. 265, no. 28, pp. 16880–16885, 1990.
- [69] G. Yang, L. Badeanlou, J. Bielawski, A. J. Roberts, Y. A. Hannun, and F. Samad, "Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome," *American Journal of Physiology*, vol. 297, no. 1, pp. E211–E224, 2009.
- [70] J. M. Adams, T. Pratipanawat, R. Berria et al., "Ceramide content is increased in skeletal muscle from obese insulin-resistant humans," *Diabetes*, vol. 53, no. 1, pp. 25–31, 2004.
- [71] E. W. Kraegen, G. J. Cooney, J. M. Ye, A. L. Thompson, and S. M. Furler, "The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in type II diabetes and obesity," *Experimental and Clinical Endocrinology and Diabetes*, vol. 109, no. 2, supplement, pp. S189–S201, 2001.
- [72] L. Pickersgill, G. J. Litherland, A. S. Greenberg, M. Walker, and S. J. Yeaman, "Key role for ceramides in mediating insulin resistance in human muscle cells," *Journal of Biological Chemistry*, vol. 282, no. 17, pp. 12583–12589, 2007.
- [73] T. Teruel, R. Hernandez, and M. Lorenzo, "Ceramide mediates insulin resistance by tumor necrosis factor- α in brown adipocytes by maintaining Akt in an inactive dephosphorylated state," *Diabetes*, vol. 50, no. 7-12, pp. 2563–2571, 2001.
- [74] S. M. De La Monte, M. Tong, M. Lawton, and L. Longato, "Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment," *Molecular Neurodegeneration*, vol. 4, no. 1, article 54, 2009.
- [75] Y. A. Hannun and L. M. Obeid, "Many ceramides," *Journal of Biological Chemistry*, vol. 286, no. 32, pp. 27855–27862, 2011.
- [76] M. Levy and A. H. Futerman, "Mammalian ceramide synthases," *International Union of Biochemistry and Molecular Biology*, vol. 62, no. 5, pp. 347–356, 2010.
- [77] Z. Z. Li, M. Berk, T. M. McIntyre, and A. E. Feldstein, "Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-Coa desaturase," *Journal of Biological Chemistry*, vol. 284, no. 9, pp. 5637–5644, 2009.
- [78] J. Bielawski, J. S. Pierce, J. Snider, B. Rembiesa, Z. M. Szulc, and A. Bielawska, "Sphingolipid analysis by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS)," *Advances in Experimental Medicine and Biology*, vol. 688, pp. 46–59, 2010.
- [79] Y. Osawa, H. Uchinami, J. Bielawski, R. F. Schwabe, Y. A. Hannun, and D. A. Brenner, "Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor- α ," *Journal of Biological Chemistry*, vol. 280, no. 30, pp. 27879–27887, 2005.
- [80] G. Seumois, M. Fillet, L. Gillet et al., "De novo C16- and C24-ceramide generation contributes to spontaneous neutrophil apoptosis," *Journal of Leukocyte Biology*, vol. 81, no. 6, pp. 1477–1486, 2007.
- [81] S. Koybasi, C. E. Senkal, K. Sundararaj et al., "Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas," *Journal of Biological Chemistry*, vol. 279, no. 43, pp. 44311–44319, 2004.
- [82] E. Boslem, G. MacIntosh, A. M. Preston et al., "A lipidomic screen of palmitate-treated MIN6 β -cells links sphingolipid metabolites with endoplasmic reticulum (ER) stress and impaired protein trafficking," *Biochemical Journal*, vol. 435, no. 1, pp. 267–276, 2011.
- [83] A. Carracedo, M. Lorente, A. Egia et al., "The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells," *Cancer Cell*, vol. 9, no. 4, pp. 301–312, 2006.
- [84] P. Hu, Z. Han, A. D. Couvillon, R. J. Kaufman, and J. H. Exton, "Autocrine tumor necrosis factor alpha links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1 α -mediated NF- κ B activation and down-regulation of TRAF2 expression," *Molecular and Cellular Biology*, vol. 26, no. 8, pp. 3071–3084, 2006.
- [85] K. D. McCullough, J. L. Martindale, L. O. Klotz, T. Y. Aw, and N. J. Holbrook, "Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state," *Molecular and Cellular Biology*, vol. 21, no. 4, pp. 1249–1259, 2001.
- [86] M. Sauane, Z. Z. Su, R. Dash et al., "Ceramide plays a prominent role in MDA-7/IL-24-induced cancer-specific apoptosis," *Journal of Cellular Physiology*, vol. 222, no. 3, pp. 546–555, 2010.
- [87] C. E. Senkal, S. Ponnusamy, J. Bielawski, Y. A. Hannun, and B. Ogretmen, "Antiapoptotic roles of ceramide-synthase-6-generated C16- ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways," *FASEB Journal*, vol. 24, no. 1, pp. 296–308, 2010.
- [88] F. Urano, X. Wang, A. Bertolotti et al., "Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1," *Science*, vol. 287, no. 5453, pp. 664–666, 2000.
- [89] F. Esfandiari, J. A. Villanueva, D. H. Wong, S. W. French, and C. H. Halsted, "Chronic ethanol feeding and folate deficiency

- activate hepatic endoplasmic reticulum stress pathway in micropigs,” *American Journal of Physiology*, vol. 289, no. 1, pp. G54–G63, 2005.
- [90] C. Ji and N. Kaplowitz, “Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice,” *Gastroenterology*, vol. 124, no. 5, pp. 1488–1499, 2003.
- [91] S. Oyadomari and M. Mori, “Roles of CHOP/GADD153 in endoplasmic reticulum stress,” *Cell Death and Differentiation*, vol. 11, no. 4, pp. 381–389, 2004.
- [92] G. H. Werstuck, S. R. Lentz, S. Dayal et al., “Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways,” *Journal of Clinical Investigation*, vol. 107, no. 10, pp. 1263–1273, 2001.



Hindawi
Submit your manuscripts at
<http://www.hindawi.com>

